Program Goals and Scope. Tobacco use is the foremost cause of premature death in the U.S. About 21% of adults are current smokers and smoking rates have not declined in recent years. Although available pharmacotherapies can aid in quitting smoking, quit rates vary substantially in subgroups of smokers. Thus, smoking is a significant clinical problem with a great need for research to improve treatment outcomes. The goal of the Pharmacogenetics of Nicotine Addiction Treatment (PNAT) research program is to generate the evidence base to optimize pharmacotherapeutic choices for individuals who wish to quit smoking. Building upon a strong foundafion of translafional pharmacogenefic (PGx) science conducted by this transdiscipiinary team during the past 4 vears. we propose in this competing renewal to: (a) conduct a multi-center prospective stratified PGx clinical trial to establish the predictive validity and cost-effectiveness of a genetically-informed biomarker to optimize smoking cessation treatment; (b) identify additional gene variants altering nicotine pharmacokinetics (PK), as well as pharmacodynamic (PD) gene variants influencing therapeutic response; and (c) elucidate causal mechanisms underiying associations of our PGx marker with smoking cessation.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01DA020830-08S1
Application #
8505449
Study Section
Special Emphasis Panel (ZRG1-ETTN-H)
Project Start
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
8
Fiscal Year
2012
Total Cost
$103,200
Indirect Cost
$31,582
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Chenoweth, Meghan J; Tyndale, Rachel F (2017) Pharmacogenetic Optimization of Smoking Cessation Treatment. Trends Pharmacol Sci 38:55-66
Ware, Jennifer J; Tanner, Julie-Anne; Taylor, Amy E et al. (2017) Does coffee consumption impact on heaviness of smoking? Addiction 112:1842-1853
Ashare, Rebecca L; Lerman, Caryn; Tyndale, Rachel F et al. (2017) Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment? J Smok Cessat 12:63-70
Tanner, Julie-Anne; Prasad, Bhagwat; Claw, Katrina G et al. (2017) Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors. J Pharmacol Exp Ther 360:129-139
Peng, Annie R; Morales, Mark; Wileyto, E Paul et al. (2017) Measures and predictors of varenicline adherence in the treatment of nicotine dependence. Addict Behav 75:122-129
Chenoweth, Meghan J; Ware, Jennifer J; Zhu, Andy Z X et al. (2017) Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. Addiction :
Tanner, Julie-Anne; Henderson, Jeffrey A; Buchwald, Dedra et al. (2017) Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. Pharmacogenet Genomics 27:169-178
Schuit, Ewoud; Panagiotou, Orestis A; Munafò, Marcus R et al. (2017) Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. Cochrane Database Syst Rev 9:CD011823
Taghavi, Taraneh; St Helen, Gideon; Benowitz, Neal L et al. (2017) Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. Pharmacogenet Genomics 27:143-154
Li, Sufang; Yang, Yihong; Hoffmann, Ewa et al. (2017) CYP2A6 Genetic Variation Alters Striatal-Cingulate Circuits, Network Hubs, and Executive Processing in Smokers. Biol Psychiatry 81:554-563

Showing the most recent 10 out of 160 publications